The DOI matches its Crossref record.
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines
Open accessAbstract
Autoimmune T and B cell responses to CNS antigen(s) are thought to drive the pathogenesis of multiple sclerosis (MS), and thus are logical targets for therapy. Indeed, several immunomodulatory agents, including IFN-β1b, IFN-β1a, glatiramer acetate, and mitoxantrone, have had beneficial clinical effects in different forms of MS. However, because the available treatments are only partially effective, MS therapy needs to be further improved. Selective (antigen-specific) immunotherapies are especially appealing because in theory they combine maximal efficacy with minimal side effects. Indeed, several innovative immunotherapies have been successfully applied in experimental autoimmune encephalomyelitis. For example, autoreactive T cells can be selectively targeted by means of antigen, T cell receptor, or activation markers. However, experimental autoimmune encephalomyelitis is far from being a perfect approximation of MS because MS is more heterogeneous and the target antigen(s) is (are) not known. Further advances in MS therapy will depend on our growing understanding of the pathogenesis of this still incurable disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Vaccines: past, present and future
Plotkin, S. A. (2005) · Nature Medicine · doi:10.1038/nm1209 · Cited by 592
Bailey, S. L., Schreiner, B., McMahon, E. J., & Miller, S. D. (2007) · Nature Immunology · doi:10.1038/ni1430 · Cited by 463
Calpain-Mediated Signaling Mechanisms in Neuronal Injury and Neurodegeneration
Vosler, P. S., Brennan, C. S., & Chen, J. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8036-x · Cited by 382
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., & Wiendl, H. (2014) · Drugs · doi:10.1007/s40265-014-0212-x · Cited by 356
Zipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
Disruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334
“IFN-β is a type I IFN with immunodulatory effects that has been used for the treatment of MS for over 15 years [86,216].”
MethodThe molecular basis of neurodegeneration in multiple sclerosis
Lassmann, H., & van Horssen, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.004 · Cited by 294
Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis
Astier, A. L., Meiffren, G., Freeman, S., & Hafler, D. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29251 · Cited by 292
Lutterotti, A., Yousef, S., Sputtek, A., Stürner, K. H., Stellmann, J.-P., Breiden, P., Reinhardt, S., Schulze, C., Bester, M., Heesen, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006168 · Cited by 281
Glial Cells as Progenitors and Stem Cells: New Roles in the Healthy and Diseased Brain
Dimou, L., & Götz, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00036.2013 · Cited by 264
Pro-cognitive properties of T cells
Kipnis, J., Gadani, S., & Derecki, N. C. (2012) · Nature Reviews Immunology · doi:10.1038/nri3280 · Cited by 246
Schulze-Topphoff, U., Prat, A., Prozorovski, T., Siffrin, V., Paterka, M., Herz, J., Bendix, I., Ifergan, I., Schadock, I., Mori, M. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1980 · Cited by 131
Metadata
- Authors
- Hohlfeld, R., & Wekerle, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-10-05
- Volume
- 101
- Issue
- suppl_2
- Pages
- 14599-14606
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2097732890
- Cited by
- 239
- References
- 0
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.